Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

Authors

Institutions

Publication Details

Journal
BMJ Open
Published
2025-02-01
DOI
https://doi.org/10.1136/bmjopen-2024-092545
Citations
1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
1.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

X. Zhu, Ying Zhu, Jianwei Zhou, Jiaojiao Zhang et al.
1 citations
BMJ Open
Ovarian cancer diagnosis and treatment
1.70
article

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

X. Zhu, Ying Zhu, Jianwei Zhou, Jiaojiao Zhang, Fei Jing, Zhigang Zhang
article en
1 citations

Abstract

No abstract available for this paper.
BMJ OpenVol. 15(2)
Second Affiliated Hospital of Zhejiang University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 20%
Ovarian cancer diagnosis and treatment
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.